Abstract
As neuropsychiatry continues the quest to improve the diagnosis and treatment of serious mental illnesses, important converging findings are beginning to take place in psychosis research with EEG-based biomarkers. Although patients with schizophrenia and related psychotic illnesses show many neurobiological abnormalities that distinguish them from healthy volunteers, the identification of these abnormalities has seldom led to tests with clinical utility, contributing to the critical need for a paradigm shift in our approach toward studying and treating these disorders (1, 2). It has been suggested that the development of next-generation therapeutics has been disappointing, due in part to a dearth of cognitive paradigms with cross-species translational validity (3) and biomarkers that can inform diagnosis or treatment. Here we propose that mismatch negativity (MMN)—a neurophysiological measure of central auditory system functioning—may be informative in developing the next generation of neuroscience-guided cognitive-enhancing treatments.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
